磷丙泊酚二钠对腹腔镜子宫切除术中年患者围手术期认知功能的影响

注册号:

Registration number:

ChiCTR2600121289 

最近更新日期:

Date of Last Refreshed on:

2026-03-27 16:38:31 

注册时间:

Date of Registration:

2026-03-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

磷丙泊酚二钠对腹腔镜子宫切除术中年患者围手术期认知功能的影响

Public title:

Effect of Disodium Phosphorylated Propofol on Perioperative Cognitive Function in Middle-Aged Patients Undergoing Laparoscopic Hysterectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

磷丙泊酚二钠对腹腔镜子宫切除术中年患者围手术期认知功能的影响

Scientific title:

Effect of Disodium Phosphorylated Propofol on Perioperative Cognitive Function in Middle-Aged Patients Undergoing Laparoscopic Hysterectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨晓慧 

研究负责人:

余得水 

Applicant:

Xiaohui Yang 

Study leader:

Deshui Yu 

申请注册联系人电话:

Applicant telephone:

+86 151 8110 9106

研究负责人电话:

Study leader's
telephone:

+86 1568039118

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

651476625@qq.com

研究负责人电子邮件:

Study leader's E-mail:

740502846@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省宜宾市翠屏区北大街96号

研究负责人通讯地址:

四川省宜宾市翠屏区北大街96号

Applicant address:

No. 96 North Street, Cuiping District, Yibin City, Sichuan Province

Study leader's address:

No. 96 North Street, Cuiping District, Yibin City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宜宾市第二人民医院

Applicant's institution:

The Second People's Hospital of Yibin City

研究负责人所在单位:

宜宾市第二人民医院

Affiliation of the Leader:

The Second People's Hospital of Yibin City

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-039-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宜宾市第二人民医院医学伦理审查委员会

Name of the ethic committee:

Medical Ethics Review Committee of The Second People's Hospital of Yibin City

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-20 00:00:00

伦理委员会联系人:

罗旭梅

Contact Name of the ethic committee:

Xumei Luo

伦理委员会联系地址:

四川省宜宾市翠屏区北大街96号

Contact Address of the ethic committee:

No. 96 North Street, Cuiping District, Yibin City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 831 825 7719

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宜宾市第二人民医院

Primary sponsor:

The Second People's Hospital of Yibin City

研究实施负责(组长)单位地址:

四川省宜宾市翠屏区北大街96号

Primary sponsor's address:

No. 96 North Street, Cuiping District, Yibin City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

宜宾市第二人民医院

具体地址:

四川省宜宾市翠屏区北大街96号

Institution
hospital:

The Second People's Hospital of Yibin City

Address:

No. 96 North Street, Cuiping District, Yibin City, Sichuan Province

经费或物资来源:

研究者课题经费

Source(s) of funding:

Researcher's project funding

研究疾病:

认知功能障碍  

Target disease:

Cognitive dysfunction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在通过一项前瞻性、随机、对照、双盲临床试验,采用非劣效性设计,验证以下假设:对于接受腹腔镜子宫切除术的中年患者,使用磷丙泊酚二钠进行麻醉,其在术后第1~3天的认知功能(主要结局指标,如MoCA评分)并不劣于使用丙泊酚。”  

Objectives of Study:

This study aims to verify the following hypothesis through a prospective, randomized, controlled, double-blind clinical trial with a non-inferiority design: for middle-aged patients undergoing laparoscopic hysterectomy, anesthesia with fospropofol disodium results in non-inferior cognitive function (the primary outcome measure, e.g., MoCA score) on the 1st to 3rd days after surgery compared with propofol anesthesia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.存在严重心、肺系统疾病; 2.术前合并痴呆、精神疾病或认知功能障碍; 3.存在交流障碍等疾病; 4.严重心血管疾病(未控制的高血压、NYHA分级>=III级、LVEF<40%、6个月内发生急性冠脉综合征或卒中); 5.肝肾功能严重异常(ALT/AST>2倍正常值上限,eGFR<60 mL/min/1.73m^2) 6.有长期服用非甾体消炎药或阿片类止痛药物史; 7.术前24h内使用其他镇痛或镇静类药物; 8.预计术中失血量大于15mL/kg或需要输血; 9.术后计划送入ICU; 10.目前处于妊娠和哺乳期。

Exclusion criteria:

1. Presence of severe cardiovascular or pulmonary diseases; 2. Preoperative dementia, mental illness, or cognitive impairment; 3. Presence of diseases causing communication disorders; 4. Severe cardiovascular diseases (uncontrolled hypertension, NYHA class ≥ III, LVEF < 40%, acute coronary syndrome or stroke within 6 months); 5. Severe liver or kidney dysfunction (ALT/AST > 2 times the upper limit of normal, eGFR < 60 mL/min/1.73m^2); 6. History of long-term use of nonsteroidal anti-inflammatory drugs or opioid analgesics; 7. Use of other analgesic or sedative drugs within 24 hours before surgery; 8. Expected intraoperative blood loss greater than 15 mL/kg or requiring blood transfusion; 9. Planned postoperative admission to ICU; 10. Currently pregnant or breastfeeding.

研究实施时间:

Study execute time:

From 2026-04-01 00:00:00 To 2027-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2026-09-01 00:00:00

干预措施:

Interventions:

组别:

丙泊酚组(P组)

样本量:

80

Group:

Propofol group (group P)

Sample size:

干预措施:

麻醉诱导时,静脉缓慢推注丙泊酚1.5~2mg/kg,麻醉维持期间,丙泊酚4-8mg/kg/h持续泵注

干预措施代码:

Intervention:

During anesthesia induction, sodium fospropofol is slowly administered intravenously at 10–12 mg/kg. During anesthesia maintenance, sodium fospropofol

Intervention code:

组别:

磷丙泊酚二钠组(F组)

样本量:

80

Group:

Phosphorylated propofol disodium group (Group F)

Sample size:

干预措施:

在麻醉诱导时,静脉缓慢推注磷丙泊酚二钠10~12mg/kg,麻醉维持期间,磷丙泊酚二钠10~15mg/kg/h持续泵注。

干预措施代码:

Intervention:

During the induction of anesthesia, propofol disodium was slowly injected intravenously at a dose of 10-12 mg/kg. During the maintenance of anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

宜宾市第二人民医院  

单位级别:

三甲 

Institution
hospital:

The Second People's Hospital of Yibin City

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后认知功能障碍发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative cognitive dysfunction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低血压发生率及持续时间

指标类型:

次要指标

Outcome:

Incidence and duration of hypotension

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

苏醒与拔管时间

指标类型:

次要指标

Outcome:

Time to emergence and extubation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PACU停留时间

指标类型:

次要指标

Outcome:

Duration of PACU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后24、48小时静息/活动VAS疼痛评分

指标类型:

次要指标

Outcome:

Rest/activity VAS pain scores at 24 and 48 hours postoperatively

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PCIA有效按压次数

指标类型:

次要指标

Outcome:

Number of effective PCIA compressions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心呕吐发生率及抢救镇痛率

指标类型:

次要指标

Outcome:

Incidence of postoperative nausea and vomiting and rescue analgesia rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时长

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉满意度评分

指标类型:

次要指标

Outcome:

Anesthesia satisfaction score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 45 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机序列将由计算机生成区组随机序列(区组大小为4)

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence will be generated by the computer as a block random sequence (block size of 4)

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对评估者设盲

Blinding:

Blinding of evaluators

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF, ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF, ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-03-27 16:37:59